Jannik Langtved Pallisgaard1,2, Tommi Bo Lindhardt1,2, Laila Staerk1,2, Jonas Bjerring Olesen1, Christian Torp-Pedersen3, Morten Lock Hansen4, Gunnar Hilmar Gislason1,2,5,6. 1. University Hospital Gentofte and Herlev, Kildegaardsvej 28, 2900 Hellerup, Copenhagen, Denmark. 2. Faculty of Health and Medical Sciences Blegdamsvej 3B, 2200, Copenhagen, Denmark. 3. Institute of Health Science and Technology, Fredrik Bajers Vej 7D, 9220 Aalborg, Denmark. 4. Zealand University Hospital Roskilde, Sygehusvej 10, 4000 Roskilde, Denmark. 5. Danish Heart Foundation, Vognmagergade 7, 3. sal, 1120 Copenhagen, Denmark. 6. National Institute of Public Health University of Southern Denmark, Oster Farimagsgade 5 A, 1353 Copenhagen, Denmark.
Abstract
Aim: The aim of this study was to investigate the association between thiazolidinediones (TZDs) vs. other antidiabetic drugs and risk of atrial fibrillation (AF) in diabetic patients. Method and results: Diabetes mellitus (diabetes) increases the risk of AF by approximately 34%. TZD is an insulin sensitizer that also has anti-inflammatory effects, which might decrease the risk of AF compared with other antidiabetic drugs. We used data from the Danish nationwide registries to study 108 624 patients with diabetes and without prior AF who were treated with metformin or sulfonylurea as first-line drugs. The incidence of AF was significantly lower with TZD as the second-line antidiabetic treatment compared with other second-line antidiabetic drugs (P < 0.001). The 10 year cumulative incidence [95% confidence interval (95% CI)] of AF was 6.2% (3.1-9.3%) with TZD vs. 10.2% (9.8-10.6%) with other antidiabetic drugs. The decreased risk of AF remained significant after adjusting for age, sex, and comorbidities with a hazard ratio (95% CI) of 0.76 (0.57-1.00), P = 0.047 associated with TZD treatment compared with other antidiabetic drugs. Conclusion: Use of a TZD to treat diabetes was associated with reduced risk of developing AF compared with other antidiabetic drugs as second-line treatment. Published on behalf of the European Society of Cardiology. All rights reserved.
Aim: The aim of this study was to investigate the association between thiazolidinediones (TZDs) vs. other antidiabetic drugs and risk of atrial fibrillation (AF) in diabeticpatients. Method and results: Diabetes mellitus (diabetes) increases the risk of AF by approximately 34%. TZD is an insulin sensitizer that also has anti-inflammatory effects, which might decrease the risk of AF compared with other antidiabetic drugs. We used data from the Danish nationwide registries to study 108 624 patients with diabetes and without prior AF who were treated with metformin or sulfonylurea as first-line drugs. The incidence of AF was significantly lower with TZD as the second-line antidiabetic treatment compared with other second-line antidiabetic drugs (P < 0.001). The 10 year cumulative incidence [95% confidence interval (95% CI)] of AF was 6.2% (3.1-9.3%) with TZD vs. 10.2% (9.8-10.6%) with other antidiabetic drugs. The decreased risk of AF remained significant after adjusting for age, sex, and comorbidities with a hazard ratio (95% CI) of 0.76 (0.57-1.00), P = 0.047 associated with TZD treatment compared with other antidiabetic drugs. Conclusion: Use of a TZD to treat diabetes was associated with reduced risk of developing AF compared with other antidiabetic drugs as second-line treatment. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Sri Harsha Patlolla; Hon-Chi Lee; Peter A Noseworthy; Waldemar E Wysokinski; David O Hodge; Eddie L Greene; Bernard J Gersh; Rowlens M Melduni Journal: Am J Cardiol Date: 2020-06-30 Impact factor: 2.778
Authors: Jannik Langtved Pallisgaard; Maria Mori Brooks; Bernard R Chaitman; Derek B Boothroyd; Marco Perez; Mark A Hlatky Journal: Am J Med Date: 2018-03-23 Impact factor: 4.965
Authors: Anna Ostropolets; Pierre A Elias; Michael V Reyes; Elain Y Wan; Utpal B Pajvani; George Hripcsak; John P Morrow Journal: Circ Arrhythm Electrophysiol Date: 2021-02-07